![Figure 1: Pre- and post-treatment scans confirmed partial responder. (From a phase I trial of riluzole and sorafenib in patients with advanced solid tumors: CTEP #8850.”)](https://www.oncotarget.net/wp-content/uploads/2023/04/Screen-Shot-2023-04-12-at-2.15.06-PM-300x193.png)
Riluzole and Sorafenib in Patients With Advanced Solid Tumors: A Phase I Trial
April 12, 2023
Our phase I study determined the tolerable dose of this combination and investigated its biologic effects.” BUFFALO, NY- April 12, 2023 – A new research paper was published in Oncotarget's... read more